CLINICAL TRIALS PROFILE FOR AMLODIPINE BESYLATE; VALSARTAN
✉ Email this page to a colleague
All Clinical Trials for AMLODIPINE BESYLATE; VALSARTAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02060019 ↗ | Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects | Completed | CJ HealthCare Corporation | Phase 1 | 2014-03-01 | This study is designated to evaluate the pharmacokinetic interactions of amlodipine besylate, valsartan and rosuvastatin in healthy male volunteers. |
| NCT02060019 ↗ | Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects | Completed | HK inno.N Corporation | Phase 1 | 2014-03-01 | This study is designated to evaluate the pharmacokinetic interactions of amlodipine besylate, valsartan and rosuvastatin in healthy male volunteers. |
| NCT02069821 ↗ | Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects | Completed | CJ HealthCare Corporation | Phase 1 | 2014-03-01 | The purpose of the study is to assess the pharmacokinetic interactions between amlodipine besylate/valsartan and atorvastatin single or co-administered in healthy volunteers. |
| NCT02069821 ↗ | Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects | Completed | HK inno.N Corporation | Phase 1 | 2014-03-01 | The purpose of the study is to assess the pharmacokinetic interactions between amlodipine besylate/valsartan and atorvastatin single or co-administered in healthy volunteers. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Haining Health-Coming Biotech Co., Ltd. | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMLODIPINE BESYLATE; VALSARTAN
Condition Name
Clinical Trial Locations for AMLODIPINE BESYLATE; VALSARTAN
Clinical Trial Progress for AMLODIPINE BESYLATE; VALSARTAN
Clinical Trial Phase
Clinical Trial Sponsors for AMLODIPINE BESYLATE; VALSARTAN
Sponsor Name
